Endoceutics, a private Quebec City-based biopharma company, entered into a long-term $85 million senior credit facility with CRG, a healthcare-focused investment firm.

The proceeds will support the commercial launch of its FDA-approved product, Intraros, and fund additional research and development in its women’s health and oncology focused pipeline.

“We are very pleased to partner with CRG due to their flexible financing structure and true healthcare investing expertise,” said Dr. Fernand Labrie, founder and chairman of Endoceutics. “The financing will assist us in supporting growth of the Intrarosa product that provides a safe, effective and superior alternative to existing estrogen-based therapies.”

“We believe that Dr. Labrie and the Endoceutics team have developed a ground-breaking and safe alternative for patients experiencing symptoms of menopause,” said Luke Duster, managing director at CRG. “Intrarosa is the first product to receive a FDA approval for this indication without a black box warning associated with estrogen-based risks.”

CRG is a healthcare-focused investment firm that delivers growth capital financing solutions to the global healthcare industry.